Rubik Therapeutics

Rubik Therapeutics is developing next generation therapies against solid tumors. Cancer genomes select for mutations that drive cancer initiation and progression, however, non-cancer associated genes in proximity can also get linked to cancer-driving lesions and become dysregulated: Rubik describes these changes as onco-linked targets. Onco-linked targets are attractive as they are selective and resistant to loss. Using their discovery engine, Rubik is decoding discoveries in cancer and immune gene regulation to identify onco-linked targets for cell therapy and other modalities. Rubik is also identifying ways to prevent suppression of the immune system.

Jobs: